Overview

Interleukin-1 Blockade in HF With Preserved EF

Status:
Completed

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

- Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure - Standard treatment for heart failure, show less than ideal results in HFpEF - Evidence of systemic inflammation is common in all forms of heart failure, including HFpEF - The main hypothesis of this study is that systemic inflammation contributes to heart failure symptoms and exercise limitations in patients with HFpEF - The main objective is to treat patients with HFpEF and evidence of systemic inflammation with an anti-inflammatory drug targeting Interleukin-1 (or placebo) to determine effects on cardiovascular function

Phase:

Phase 2

Details

Lead Sponsor:

Virginia Commonwealth University

Collaborator:

National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Interleukin 1 Receptor Antagonist Protein